As the digital transformation of clinical research and the adoption of decentralized clinical trials continue to gain momentum, sponsors are increasingly using wearable motion-sensing technologies to capture real-world digital biomarker data. In exchange for the valuable insights into treatment efficacy and quality of life they provide, successful wearable technology deployments require a significant investment of time and resources from clinical trial sponsors, their partners and the patients they serve. By leveraging a sensor platform that collects and provides access to “future-proof” raw source data, sponsors can generate reusable clinical data assets that maintain their value over time, even as sophisticated analytic techniques and novel algorithms emerge.
Register for this one-hour educational webinar, where data experts from ActiGraph and Koneksa will present a roadmap to help clinical trial sponsors and their partners design and implement a “future-proof” raw data strategy to maximize the long-term value of digital biomarker data. Speakers will identify and discuss some of the key considerations for selecting a digital measure and wearable sensor while providing practical guidance for overcoming the inherent challenges and obstacles that many clinical development teams encounter along the way.
Jeremy Wyatt, Chief Executive Officer, ActiGraph
Jeremy Wyatt is the CEO of ActiGraph, a leading global provider of physical activity and sleep monitoring solutions for pharmaceutical and academic industries. With two decades of embedded hardware systems development and related cloud technology expertise, Jeremy has a uniquely well-rounded perspective on the challenges and opportunities of deploying wearable technologies to capture accurate and meaningful patient data.
He is considered an industry thought leader and expert in the clinical biosensor space and is a frequent representative and contributor at clinical drug development commercial events, scientific consortiums and FDA/EMA regulatory meetings. He has an undergraduate degree in electrical engineering from the University of Florida and an MBA from the University of West Florida. Jeremy is a member and contributor to the Digital Medicine (DiMe) Society and participates in various digital biomarker efforts with the Clinical Trial Transformation Initiative (CTTI).Message Presenter
Tyler Guthrie, Director of Scientific Affairs & Data Management, ActiGraph
Tyler Guthrie is the Director of Scientific Affairs and Data Management at ActiGraph. As an internal SME, Tyler’s primary role is educating members of the life sciences community about how and why to collect raw biosensor data, how these data are transferred and managed and what processing and algorithms are applied to the data.Message Presenter
Robert Ellis, Ph.D., Head of Data Science, Koneksa
Robert Ellis, Ph.D., leads Koneksa’s data sciences team. Robert works with an internal team of algorithm developers, data scientists, and statisticians focused on algorithm development, validation activities, and the development of next-generation digital measures. Robert has a Ph.D. in geophysics and more than ten years of experience in enterprise-technology leadership at the SVP/CTO level.Message Presenter
Who Should Attend?
- Clinical Operations
- Data Managers
- Innovation Managers
- Research and Development
- Technology Leaders and Experts
What You Will Learn
In this webinar, participants will learn about:
- Understanding the key differences between raw and processed biosensor data
- A retrospective look at why raw data is so valuable
- Factors that influence the integrity of raw data and how to plan for them
- Key operational considerations around remote data capture
ActiGraph’s mission is to bring life to digital data. Built on more than twenty years of remote data capture expertise, ActiGraph is the leading provider of medical-grade wearable motion sensors for the global scientific community. ActiGraph’s FDA-cleared biosensors and flexible technology ecosystem deliver high quality, continuous digital data, providing valuable insights into the real-world behaviors of clinical trial participants. Appearing in more than 17,000 published scientific papers to date, ActiGraph is the industry’s most experienced, knowledgeable.